NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Samson DJ, Ratko TA, Rothenberg BM, et al. Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. (Comparative Effectiveness Reviews, No. 20.)

Cover of Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer

Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer [Internet].

Show details

Abbreviations

Δ

change

~

approximately

1o

primary

2.5D

2 ½ D RT

2D

two-dimensional

2DRT

2D conventional RT

3D

three dimensional

3DC

3D conformal RT

3DCRT

3D conformal radiotherapy

ACC

accelerated fractionation

AdjCtx

adjuvant chemoradiotherapy

AHRQ

Agency for Healthcare Research and Quality

ASCO

American Society of Clinical Oncology

ASTRO

American Society of Therapeutic Radiation Oncology

AUD

auditory acuity

BON

bone

BOT

base of tongue

BRA

brachytherapy

BRN

brain AEs

BST

boost dose

CCRTx

concurrent chemoradiotherapy

CER

comparative effectiveness review

CHT

chemotherapy only

CNT

central nervous system tumor (including spine)

CRN

cranial nerve tumors

CRT

chemoradiotherapy

CT

computed tomography

CTP

cytoprotective agent

CTV

clinical target volume

CUT

cutaneous tumors (melanoma, etc.)

def

definitive

DFR

definitive RT

DFS

disease-free survival

DNT

dental AEs

DS?

disease unclear

DSS

(cancer) disease-specific survival

DYS

dysphagia

Dx

diagnosis

EAR

ear tumors

EORTC

European Organization for Research and Treatment of Cancer

EPC

Evidence-based Practice Center

EPICOT

Evidence, Population, Intervention, Comparators, Outcome, Time stamp

ESO

esophagus AEs

EST

esophageal or precursors

ETH

ethmoid sinus

EYE

eye tumors

F/U

followup

F/U?

followup uncertain

freq

frequency

Gr

grade

grnd

ground

GTV

gross tumor volume

Gy

Gray

Hb

hemoglobin

HEM

hematologic tumor (including lymphoma

HN

head and neck

HNCI

Head and Neck Cancer Inventory

HNQOL

Head and Neck Cancer-Specific Quality of Life

HNU

head & neck unspecified

HPV

human papillomavirus

HRT

heart AEs

HYF

hyperfractionation

HYP

hypopharyngeal

ICBT

intracavitary brachytherapy

IMM

with immobilization

IMR

IMRT

IMRT

intensity modulated radiotherapy

ITT

intention to treat

LAR

laryngeal

LC

local control

LDH

lactate dehydrogenase

LFF

local failure free

LFFR

local freedom from recurrence

LN

lymph node

LNG

lung AEs

LR

locoregional

LRC

locoregional control

LRPFS

locoregional progression-free survival

LRRFS

locoregional recurrence-free survival

LX

larynx AEs

MAX

maxillary sinus

MET

metastatic

mets

metastases

MFS

(distant) metastasis-free survival

MIX

mixed head and neck

MLT

major late toxicities

mod

moderate

mo(s).

month(s)

MUC

mucous membrane AEs

MVA

multivariable analysis

NA

not applicable

NBT

neutron beam therapy

NCCN

National Comprehensive Cancer Network

NCI CTC

National Cancer Institute’s Common Toxicity Criteria

NeoadjCtx

neoadjuvant chemoradiotherapy

NPC

nasopharyngeal cancer

NPH

nasopharyngeal

NR

not reported

NRD

not relevant disease

NRO

not relevant outcome (or no follow-up)

NRT

not relevant treatment

NS

not significant

NV

nausea/vomiting

O?

outcome unclear

OAE

other AE

OCL

oral cavity/lip

OCU

ocular AEs

OHN

other head and neck tumor

OLF

olfactory AEs

OPH

oropharyngeal

ORN

osteoradionecrosis

OS

overall survival

OST

other non-head and neck solid tumor

OTE

other time-to-event outcome

OTO

otologic/auditory AEs

PAL

palliative

PAR

paraganglioma

PBT

proton beam therapy

PCR

postoperative CRT

pctg

percentage

PDQ

Physician Data Query

PFS

progression-free survival

PHR

pharyngeal

PHX

pharynx

PNS

paranasal sinus/nasal cavity

postop

postoperative

postopRT

postoperative radiotherapy

postRT

after radiotherapy

PRE

preoperative (neoadjuvant)

preop

preoperative

preopRT

preoperative radiotherapy

preRT

before radiotherapy

Pro

prospective

prob(s)

probability(ies)

PS

performance status

PST

postoperative (adjuvant)

PTH

parathyroid

PTV

planning target volume

Q#?

unclear if relevant to any key question

QLQ

Quality of Life Questionnaire

QOL

quality of life

RCT

randomized, controlled trial

REC

recurrent (reirradiation)

ReRT

reirradiation

Retro

retrospective

RSE

radiosensitizing agent

RSP

tumor response

RT

radiotherapy

RTOG

Radiation Therapy Oncology Group

SAL

salivary gland, including parotid

SB

skull base tumors

SCC

small cell cancer

sev

severity

SF-36

Short Form-36

SIN

sinus unspecified

SKN

skin AEs

SLF

salivary flow

SOMA

Subjective, Objective, Management, Analytic

SPN

spinal cord AEs

SRS

stereotactic radiosurgery

SRT

stereotactic radiotherapy

SUB

subcutaneous tissue AEs

SUR

surgery only

Sx

symptoms

T?

treatment unclear

TAE

toxicity/adverse events (not specified)

TEP

Technical Expert Panel

THY

thyroid

TR

tracheal tumors

TRD

treatment-related death

TTR

time-to-recurrence

Tx

treatment

UA

univariate analysis

UCF

unspecified conformal RT

UNP

unknown/occult primary

URT

unspecified radiotherapy

USPSTF

U.S. Preventive Services Task Force

UWQOL

University of Washington Quality of Life

VAS

visual analog scale

VSA

visual acuity

XQ

xerostomia questionnaire

XST

xerostomia

yr(s)

years

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...